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Background. It is hypothesized, but not proven, that perito-
neal dialysis might be the optimal treatment for end-stage renal
disease (ESRD) patients with established congestive heart fail-
ure (CHF) through better volume regulation compared with
hemodialysis.
Methods. National incidence data on 107,922 new ESRD
patients from the Center for Medicare and Medicaid Services
(CMS) Medical Evidence Form were used to test the hypothesis
that peritoneal dialysis was superior to hemodialysis in pro-
longing survival of patients with CHF. Nonproportional Cox
regression models evaluated the relative hazard of death for
patients with and without CHF by dialysis modality using pri-
marily the intent-to-treat but also the as-treated approach.
Diabetics and nondiabetics were analyzed separately.
Results. The overall prevalence of CHF was 33% at ESRD
initiation. There were 27,149 deaths (25.2%), 5423 transplants
(5%), and 3753 (3.5%) patients lost to follow-up over 2 years.
Adjusted mortality risks were significantly higher for patients
with CHF treated with peritoneal dialysis than hemodialysis
[diabetics, relative risk (RR)  1.30, 95% confidence interval
(CI) 1.20 to 1.41; nondiabetics, RR 1.24, 95% CI 1.14 to 1.35].
Among patients without CHF, adjusted mortality risk were
higher only for diabetic patients treated with peritoneal dialysis
compared with hemodialysis (RR 1.11, 95% CI 1.02 to 1.21)
while nondiabetics had similar survival on peritoneal dialysis
or hemodialysis (RR  0.97, 95% CI 0.91 to 1.04).
Conclusion. New ESRD patients with a clinical history of
CHF experienced poorer survival when treated with peritoneal
dialysis compared with hemodialysis. These data suggest that
peritoneal dialysis may not be the optimal choice for new
ESRD patients with CHF perhaps through impaired volume
regulation and worsening cardiomyopathy.
Recent mortality comparisons of peritoneal dialysis and
hemodialysis among new end-stage renal disease (ESRD)
patients have suggested that survival on peritoneal dial-
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ysis is at least similar to that of hemodialysis if not better
within the first 2 years of therapy [1–3]. Accordingly, the
general consensus is that peritoneal dialysis and hemodi-
alysis can be viewed as “equivalent therapies” and there-
fore either modality may be used as primary therapy
for most newly diagnosed patients provided there are no
contraindications [4]. There has been speculation, how-
ever, that the type and nature of dialysis treatment pro-
vided to ESRD patients may play a pathogenetic role
in enhancing cardiovascular disease progression and car-
diovascular mortality, especially among those with pre-
existing cardiac conditions [5–9].
Given that cardiac disease is the leading cause of death
in this population, defining the optimal modality strategy
for new ESRD patients, especially those with preexisting
cardiac disease, may help reduce future morbidity and
mortality. In a recent publication, we have shown that the
survival of patients at ESRD onset with known coronary
artery disease (CAD) differs with respect to treatment
modality [10]. Patients with CAD had significantly poorer
survival at 2 years when treated with peritoneal dialysis
compared with hemodialysis. These data suggested that
peritoneal dialysis, as currently practiced, might not be
the optimal choice for new ESRD patients with preexist-
ing CAD possibly because of accelerated cardiovascular
disease.
It is widely assumed, but not proven, that ESRD pa-
tients with congestive heart failure (CHF) benefit more
from peritoneal dialysis than from hemodialysis. Most
observations supporting the role of peritoneal dialysis as
an efficient volume control therapy have come from single-
center studies in the general population [11–15]. These
have shown that, among patients with refractory CHF,
the choice of peritoneal dialysis is associated with sig-
nificantly lower hospitalization rates and improved func-
tional status compared with medical therapy. Among
ESRD patients with CHF, it is unclear whether perito-
neal dialysis confers a survival advantage over hemodial-
ysis. Theoretically, peritoneal dialysis may be superior
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to hemodialysis in regulating volume control and pre-
venting further structural cardiac impairment because of
continuous ultrafiltration and fewer hemodynamic con-
sequences. The purpose of this study was to explore the
hypothesis that patients new to ESRD with a history of
CHF experience greater survival with peritoneal dialysis
compared to hemodialysis.
METHODS
Data
This hypothesis was tested in a historical prospective
cohort of new ESRD patients in the United States, initi-
ated on dialysis between May 1, 1995 and July 31, 1997.
Data sufficient for these analyses were obtained from
the Standard Analysis Files (SAFs) of the United States
Renal Data System (USRDS). The Medical Evidence
SAF is derived from the Center for Medicare and Medic-
aid Services (CMS) Medical Evidence Form, a govern-
ment document that is completed for all new patients
initiated on dialysis [16]. The CMS form records data
on demographic characteristics, comorbid conditions, lab-
oratory indices, date of first dialysis, and type of treatment
provided for all incident patients. CHF was defined on
the presence or absence of this condition from the Medi-
cal Evidence Form. Covariates representing the follow-
ing conditions were also included: age (modeled as a con-
tinuous variable), gender (male vs. female), race (white,
black, Asian versus other), ethnicity (Hispanic versus non-
Hispanic), diabetes (defined as a cause of ESRD), diabe-
tes (as cause of ESRD or recorded comorbid condition),
history of hypertension, CAD (defined as a history of prior
CAD, myocardial infarction, angioplasty or coronary ar-
tery bypass graft), history of cardiac arrythmia or cardiac
arrest, cerebrovascular disease (defined as a history of prior
cerebrovascular accident or transient ischemic attack), his-
tory of chronic lung disease, tobacco use, malignant neo-
plasm or cancer, and acquired immunodeficiency syn-
drome (AIDS). Body mass index (BMI) was calculated
from the equation: BMI  weight (kg)/height (m2). In
addition, data were also available for the following labo-
ratory indices: serum creatinine, blood urea nitrogen,
serum albumin, and hematocrit. Residual renal function
at ESRD initiation was estimated from the Modification
of Diet in Renal Disease (MDRD) formula [17].
Treatment modality, hemodialysis or peritoneal dial-
ysis for each patient was determined from the USRDS
Treatment History SAF [18]. The USRDS uses a com-
plex analytic process from a variety of data sources to
determine dialysis modality at ESRD onset and at any
point in time thereafter. These data sources include the
Medical Evidence Form, the Quarterly Dialysis File, and
the Medicare Claims Files. Any switches in treatment
modality, from hemodialysis to peritoneal dialysis or
peritoneal dialysis to hemodialysis during follow-up are
recorded in the data files and can be used to define the
total period for which patients remained on a specific
therapy. The definition of switch was based on the 60-
day rule as suggested by the USRDS. This rule requires
that a patient be on a new modality for at least 60 days
before it is considered to be a change in modality [18].
The study start date for all incident patients was defined
as day 90 of ESRD. The reasons for this are twofold.
First, many patients younger than 65 do not become
eligible for Medicare for up to 90 days and therefore
may have incomplete claims data prior to this. Second,
the 90-day rule is important for patients whose final
modality is peritoneal dialysis but who have been placed
temporarily on hemodialysis until peritoneal dialysis
training has been completed. The Medical Evidence
Form and Treatment History datasets were merged with
mortality and transplantation data from the USRDS.
This allowed merging of data on date of death and date
of renal transplantation by USRDS identification num-
ber for each member of the study.
Patient population
There were 158,685 patients, age 18 years and older,
who were initiated on dialysis from May 1, 1995 to July
31, 1997. Patients were excluded from the analysis if they
had received a renal transplant within the first 90 days
of ESRD initiation, if modality assignment could not be
determined at day 90 of ESRD, or if data were missing
on demographic, comorbid, and laboratory variables of
interest. Following exclusions, there were 107,922 adult
patients available for this analysis.
Analytic methods
Time-dependent Cox regression equations compared
the mortality risks of hemodialysis with peritoneal dialysis
in patients with and without CHF with adjustment for
potential confounders. Covariates for adjustment included
age at study start, gender (male versus female), race (white
versus other race), hypertension, peripheral vascular and
cerebrovascular disease, tobacco use, chronic obstructive
lung disease, history of cardiac arrest/arrhythmia, AIDS,
neoplasm, BMI, serum albumin, hematocrit, estimated
glomerular filtration rate (GFR), and pre-ESRD eryth-
ropoietin use.
Patient survival times on peritoneal dialysis and hemo-
dialysis were compared at successive 6-month intervals
during follow-up and censored at death, loss to follow-
up, or at the end of 2 years, whichever came first. “Intent-
to-treat” and “as-treated” models evaluated the associa-
tion of treatment modality with mortality risk in patients
with and without CHF. In the “intent-to-treat” analyses,
patients were not censored if they changed treatment
modality during follow-up and patient death was assigned
to the initial treatment modality. In the “as-treated” analy-
ses, patients were censored from contributing additional
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Table 1. Characteristics of the study population at end-stage renal disease (ESRD) onset from the Center for Medicare and Medicaid
Services (CMS) Medical Evidence Report Form (N  107,922)
Study population Hemodialysis Peritoneal dialysis
Patient characteristics N  107,922 N  93,900 N  14,022
Demographics
Age of onset of ESRD (mean yearsSD) 61.515.3 62.315.2 56.515.2f
Race
% White 63.4 62.0 73.4f
% Black 31.1 32.6 20.8f
% Asian 3.7 3.6 4.2e
Gender % male 53 52.8 53.8d
Cause of ESRD % diabetes 44.3 44.0 46.1f
Laboratory values (mean  SD)
Serum albumin g/dL 3.20.7 3.20.65 3.40.64f
Hematocrit % 28.15.3 27.95.3 29.35.3f
Glomerular filtration rate (MDRD) mL/mina 7.02.8 7.02.8 7.32.8f
Comorbid conditions % yes
Diabetes (history and/or nephropathy) 39.3 39.4 38.7
Hypertension 72.6 72.5 73.2
Coronary artery diseaseb 25.9 26.4 22.7f
Myocardial infarction 8.9 9.0 8.4d
Cardiac arrest/dysrhythmia 6.4 6.5 5.3f
Congestive heart failure 32.7 33.9 24.7f
Cerebrovascular disease 8.9 9.3 6.7f
Peripheral vascular diseasec 14.6 15.0 12.1f
Chronic obstructive lung disease 6.9 7.3 4.4f
Tobacco use 6.2 6.2 6.4
AIDS 0.55 0.57 0.41d
Neoplasm 4.9 5.2 3.0f
Body mass index (mean kg/m2SD) 25.75.8 25.65.9 25.95.3f
a At first dialysis per MDRD formula [17]
b Includes history of coronary artery disease, myocardial infarction, coronary artery bypass surgery, angioplasty or abnormal angiography
c Includes a history of peripheral vascular disease amputation, intermittent claudication or absent pulses
dP  0.05; e P  0.01; f P  0.001 for bivariate comparisons
time at risk when they switched from one modality of
treatment to another. Moreover, the “as-treated” data
allowed us to evaluate the mortality risks of patients
who switched from one modality to another during the
follow-up period by comparing survival times of patients
who switched from peritoneal dialysis to hemodialysis
(HDnew) and from hemodialysis to peritoneal dialysis
(PDnew) with those remaining on peritoneal dialysis (PDo)
or hemodialysis (HDo) since ESRD start. Diabetics and
nondiabetics were analyzed in separate models as prior
studies have shown nonproportional hazards. Statistic
analyses were performed using SAS statistical software
(Version 8.0 SAS Institute, Cary, NC, USA).
RESULTS
Baseline characteristics of the study cohort
The study cohort consisted of 107,922 patients who
were initiated on dialysis between May 1, 1995 and July
31, 1997. Table 1 illustrates the characteristics of the
entire cohort at study entry and according to the initial
mode of dialysis. Hemodialysis was the initial modality
for 93,900 (87%), peritoneal dialysis for 14,022 (13%)
and the prevalence of CHF was 33%. The average age
at onset of ESRD was 61.5  15 years, 63% were white,
53% were male, and 44% had ESRD from diabetes.
The demographic and clinical characteristics of patients
excluded as a result of incomplete or missing data were
nearly identical to those of the study population. At base-
line, patients on peritoneal dialysis differed from those on
hemodialysis with respect to demographic and comorbid
characteristics. Patients treated with peritoneal dialysis
were younger in age and had fewer comorbid conditions
than their hemodialysis counterparts. Overall, peritoneal
dialysis patients had significantly lower prevalence of
CAD (22.7% versus 26.4%), CHF (24.7% versus 33.9%),
cerebrovascular disease (6.7% versus 9.3%), peripheral
vascular disease (12.1% versus 15.0%), chronic lung dis-
ease (4.4% versus 7.3%), and cancer (3.0% versus 5.2%).
Moreover, peritoneal dialysis–treated patients had signif-
icantly higher hematocrit (29.3% 5.3% versus 27.9%
5.3%), and albumin levels (3.4 g/dL  0.64 g/dL versus
3.2 g/dL 0.65 g/dL) and greater residual renal function
at ESRD onset compared to patients treated with hemo-
dialysis (7.3 mL/min  2.8 mL/min versus 7.0 mL/min 
2.8 mL/min). Table 2 compares the characteristics of
patients with and without CHF by treatment modality.
The distribution of patients characteristics among pa-
tients without CHF treated with peritoneal dialysis were
similar to that of the overall peritoneal dialysis cohort
with fewer comorbid conditions and better laboratory
indices among these peritoneal dialysis patients com-
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Table 2. Characteristics of patients with and without congestive heart failure (CHF) by treatment modality at end-stage renal disease
(ESRD) onset (N  107,922)
CHF present (N  35,285) CHF absent (N  72,637)
Hemodialysis Peritoneal dialysis Hemodialysis Peritoneal dialysis
Patient characteristics (N  31,824) (N  3461) (N  62,076) (N  10,561)
Demographics
Age of onset of ESRD (mean yearsSD) 67.112.4 63.512.6e 59.815.9 54.315.3
Race
% White 68.2 79.8e 58.7 71.3e
% Black 27.4 16.4e 35.3 22.3e
% Asian 3.0 2.6 4.7 4.0d
Gender % male 49.5 53.5e 54.6 53.9
Cause of ESRD % diabetes 54.1 60.4e 38.8 41.7e
Laboratory Values (mean  SD)
Serum albumin g/dL 3.10.61 3.30.60e 3.20.67 3.50.65e
Hematocrit % 28.35.1 29.85.2e 27.75.4 29.25.4e
Glomerular filtration rate (MDRD) mL/mina 7.72.9 8.23.0e 6.72.6 7.02.6e
Comorbid Conditions (% yes or suspected)
Diabetes (history and/or nephropathy) 50.8 53.3d 33.5 33.9
Hypertension 79.2 78.8 69.0 71.4e
Cardiac arrest/dysrhythmia 12.5 12.9 3.4 2.8d
Coronary artery disease 46.3 49.3d 16.2 14.0e
Cerebrovascular disease 12.6 11.2c 7.6 5.3e
Peripheral vascular diseaseb 24.9 25.4c 10.0 7.8e
Chronic lung disease 12.4 9.5e 4.6 2.7e
Tobacco use 6.5 6.1 6.4 6.1
AIDS 0.18 0.23 0.78 0.47d
Neoplasm 5.1 3.6e 5.3 2.8e
Body mass index (mean kg/m2SD) 25.75.9 25.85.3 25.65.9 25.95.3e
a At first dialysis per MDRD formula [17]
b Includes a history of peripheral vascular disease amputation, intermittent laudication or absent foot pulses
c P  0.05; d P  0.01; e P  0.001 for bivariate comparisons in each CHF category
pared to hemodialysis patients. In contrast, among pa-
tients with CHF, the distribution of comorbid conditions
in peritoneal dialysis and hemodialysis-treated patients
were similar with some exceptions. CAD (49.3% versus
46.3%), peripheral vascular disease (25.4% versus 24.9%),
and diabetes (53.3% versus 50.8%) were more common
in the peritoneal dialysis group.
Patient survival
The median follow-up was 12 months; 27,149 (25.2%)
patients died, 5423 (5%) were transplanted, and 3753
(3.5%) patients were lost to follow-up within the 2-year
period. Adjusted Cox survival curves were estimated for
peritoneal dialysis and hemodialysis-treated patients in
each CHF category as shown in Figures 1 and 2. Overall
survival was significantly poorer for new ESRD patients
with CHF compared to those without CHF in both the
diabetic (Fig. 1) and nondiabetic (Fig. 2) cohorts. For
diabetic patients with CHF, the survival curves begin to
diverge at 6 months and continue thereafter with signifi-
cantly poorer survival for peritoneal dialysis–treated pa-
tients. For diabetics without CHF, there was an early
increased hazard for hemodialysis patients (during the
first 9 months of therapy); however, survival curves
crossed after 9 months with a less favorable outcome
for peritoneal dialysis patients observed thereafter. For
nondiabetics with CHF, the estimated survival functions
were almost identical to those for diabetic CHF patients.
Fig. 1. Adjusted Cox survival curves for new diabetic end-stage renal
disease (ESRD) patients with and without congestive heart failure
(CHF) treated with peritoneal dialysis (PD) versus hemodialysis (HD).
Adjusted for age at study start, gender, race, cause of ESRD, hyperten-
sion, coronary artery disease (CAD), peripheral vascular and cerebro-
vascular disease, tobacco use, chronic lung disease, acquired immuno-
deficiency syndrome (AIDS), neoplasm, serum albumin, body mass
index (BMI), hematocrit, estimated glomerular filtration rate (GFR),
and pre-ESRD erythropoietin use. For CHF, PD/HD comparison, P 
0.0001; no CHF PD/HD comparison, P  0.01.
In contrast, among nondiabetic patients without CHF,
survival curves were almost superimposed.
Mortality risk predictors in new ESRD patients
The relationship between treatment modality and sub-
sequent mortality risk was explored for the entire cohort
and the unadjusted and adjusted hazard ratios with 95%
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Fig. 2. Adjusted Cox survival curves for new nondiabetic end-stage
renal disease (ESRD) patients with and without congestive heart failure
(CHF) treated with peritoneal dialysis (PD) versus hemodialysis (HD).
Adjusted for age at study start, gender, race, cause of ESRD, hyperten-
sion, coronary artery disease (CAD), peripheral vascular and cerebro-
vascular disease, tobacco use, chronic lung disease, acquired immunode-
ficiency syndrome (AIDS), neoplasm, serum albumin, body mass index
(BMI), hematocrit, estimated glomerular filtration rate (GFR), and pre-
ESRD erythropoietin use. For CHF, PD/HD comparison, P  0.0001;
no CHF PD/HD comparison, P  NS.
confidence intervals (95% CI) for each covariate are
given in Table 3. The relative risk of death for peritoneal
dialysis versus hemodialysis varied significantly over time.
The unadjusted analysis found a lower risk of death for
peritoneal dialysis compared to hemodialysis-treated pa-
tients up to 12 months’ follow-up, an equalization of risk
at between 12 and 18 months and significantly higher risk
of death during 18 to 24 months [relative risk (RR) 
1.11, 95% CI 1.01 to 1.21]. With adjustment, however,
the benefit of peritoneal dialysis over hemodialysis was
observed only in the first 6 months of dialysis, after which
peritoneal dialysis patients experienced significantly
higher mortality risk compared to their hemodialysis
counterparts (RR 1.15, 1.28, and 1.37 at each 6-month
interval, respectively, P  0.001).
Mortality risks of peritoneal dialysis and hemodialysis
in patients with and without CHF: Intent-to-treat
The finding of significant interactions between treat-
ment modality, CHF, and survival, as well as treatment
modality, diabetes, and survival (P  0.001 for each)
permitted us to investigate these relationships further
in a series of time-dependent Cox regression models
stratified by diabetes and CHF. The unadjusted and ad-
justed RR estimates are presented in Table 4.
Among diabetics with CHF, the unadjusted mortality
risk of peritoneal dialysis versus hemodialysis varied
over time and was significantly higher for peritoneal dial-
ysis patients between 6 and 24 months of follow-up. With
adjustment for differences in demographic factors, mea-
sures of nutrition, and cardiovascular conditions between
peritoneal dialysis and hemodialysis, an even stronger
relationship was evident with significantly higher mortal-
ity risk for peritoneal dialysis–treated patients (RR 
1.14, 1.37, 1.50, and 1.39 at each successive 6-month time
period, respectively). A similar pattern in risk was ob-
served among diabetics without CHF with higher death
risk between 6 and 24 months of follow-up.
Among nondiabetics, the modality CHF interaction
with mortality was also highly significant (P  0.0001),
indicating that the impact of dialysis treatment on sur-
vival was different in patients with and without CHF. In
the stratified analysis, patients with CHF treated with
peritoneal dialysis had significantly higher adjusted mor-
tality risk compared to those who received hemodialysis
between 6 and 24 months of follow-up (RR  1.11,
1.28, 1.35, and 1.47 at each successive 6-month interval,
respectively). Similarly, the hazard ratios of peritoneal
dialysis versus hemodialysis in nondiabetic patients with-
out clinical CHF also varied over time but in contrast
peritoneal dialysis–treated patients experienced a lower
mortality risk during the first 6 months, similar risk be-
tween 6 and 12 months, and significantly higher risk
between 12 and 24 months compared to hemodialysis-
treated patients (RR  0.79, 1.01, 1.20, and 1.36 at each
successive 6-month period, respectively).
Mortality risks of peritoneal dialysis and hemodialysis
in patients with and without CHF: As-treated analysis
The results of the time-dependent as-treated analyses
mirrored those of the intent-to-treat analysis and are
presented in Table 5. Among diabetics with CHF, the
adjusted mortality risk was significantly higher for perito-
neal dialysis patients who remained on this therapy dur-
ing follow-up (PDo/HDo  1.29, P  0.0001) and for
patients who switched therapies either from peritoneal
dialysis to hemodialysis (HDnew/HDo 1.50, P 0.0001)
or from hemodialysis to peritoneal dialysis (PDnew/HDo
1.72, P  0.0001) compared to those who remained on
hemodialysis from ESRD start. For diabetics without
CHF who did not switch; survival was similar either on
PDo or HDo (RR  1.02, P  NS), while those who
switched from peritoneal dialysis to hemodialysis and
from hemodialysis to peritoneal dialysis had substan-
tially higher mortality risks, by 72% and 39%, respec-
tively. Among nondiabetics stratified by CHF, the results
of the as-treated analysis again paralleled those of the
intent-to treat analysis. In the CHF subgroup, PDo pa-
tients experienced a 21% higher mortality risk compared
to HDo patients during follow-up, while those who
switched therapies had substantially greater risks, 54%
(HDnew) and 45% (PDnew), respectively. In contrast, PDo
patients in the non-CHF group had a 10% lower mortal-
ity risk compared to HDo patients following adjustment,
while those who switched had significantly greater risks,
46% for HDnew and 28% for PDnew.
Several sensitivity analyses evaluated the robustness
of our observations. First, we repeated the regression
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Table 3. Predictors of all-cause mortality in new end-stage renal disease (ESRD) patients in the United States (N  107,922)
Patient characteristics Unadjusted relative riska 95% CI Adjusted relative riska 95% CI
Demographics
Age of onset of ESRD years 1.04 1.035–1.037h 1.03 1.030–1.032h
White race (nonwhite) 1.53 1.49–1.57h 1.25 1.22–1.29h
Male gender (female) 1.02 0.99–1.04 0.99 0.97–1.02
Diabetic ESRD (all other causes) 1.10 1.08–1.13h 1.08 1.05–1.11h
Laboratory values
Serum albumin per 1 g/dL 0.75 0.73–0.76h 0.72 0.71–0.73h
Hematocrit per 1% 1.02 1.015–1.020h 1.01 1.010–1.014h
Glomerular filtration rate (MDRD) per mL/minb 1.08 1.07–1.08h 1.05 1.046–1.055h
Comorbidity (yes or suspected versus no)
Coronary artery diseasec 1.68 1.64–1.73h 1.11 1.08–1.14h
Cardiac arrest/dysrhythmia 1.86 1.78–1.93h 1.18 1.14–1.23h
Congestive heart failure 1.72 1.68–1.76h 1.26 1.23–1.29h
Cerebrovascular disease 1.58 1.53–1.64h 1.18 1.13–1.22h
Peripheral vascular diseased 1.66 1.61–1.71h 1.18 1.14–1.22h
Chronic obstructive lung disease 1.82 1.75–1.90h 1.24 1.19–1.29h
Tobacco use 1.01 0.96–1.07 1.03 0.98–1.09
AIDS 2.62 2.33–2.95h 4.91 4.37–5.52h
Neoplasm 1.81 1.73–1.90h 1.42 1.36–1.49h
Body mass index (per kg/m2) 0.963 0.960–0.965h 0.98 0.974–0.978h
Pre-ESRD care
Erythropoeitin use (yes vs no) 0.90 0.87–0.93h 0.86 0.84–0.89h
Dialysis modality
Peritoneal dialysis versus hemodialysis (reference)e
0–6 months 0.69 0.65–0.73h 0.92 0.87–0.98h
6–12 months 0.91 0.86–0.97g 1.15 1.08–1.23h
12–18 months 1.06 0.99–1.13 1.28 1.19–1.38h
18–24 months 1.11 1.01–1.21f 1.37 1.25–1.51h
0–24 months 0.83 0.80–0.87h 1.11 1.07–1.16h
a Unadjusted and adjusted relative risks for all covariates in the study population
b At first dialysis per MDRD formula [17]
c Includes history of coronary artery disease, myocardial infarction, coronary artery bypass surgery, angioplasty, or abnormal angiography
d Includes a history of peripheral vascular disease amputation, intermittent claudication, or absent foot pulses
e Relative risks for peritoneal dialysis versus hemodialysis were estimated at each successive 6-month interval. A separate model found significant interactions
between modality  congestive heart failure (CHF) (P  0.0001) and modality  diabetes (P  0.0001) when included in the adjusted model.
f P  0.05; gP  0.01; hP  0.001 compared to a relative risk of 1.00
Table 4. Relative risk of death for peritoneal dialysis (PD) versus hemodialysis (HD) among incident end-stage renal disease (ESRD)
patients with and without preexisting congestive heart failure (CHF): Intent-to treat analysis
CHF relative risk (PD/HD) No CHF relative risk (PD/HD)
Time months Unadjusted Adjusted (95% CI) Unadjusted Adjusted (95% CI)
Diabetic population
0–6 1.05 (0.94, 1.18) 1.14 (1.01, 1.28)a 0.68 (0.60, 0.78)c 0.93 (0.82, 1.07)
6–12 1.28 (1.12, 1.46)c 1.37 (1.20, 1.57)c 1.07 (0.94, 1.21) 1.31 (1.16, 1.49)c
12–18 1.45 (1.25, 1.69)c 1.50 (1.29, 1.75)c 1.17 (1.02, 1.34)a 1.39 (1.21, 1.61)c
18–24 1.35 (1.09, 1.65)a 1.39 (1.12, 1.72)b 1.12 (0.93, 1.34) 1.32 (1.09, 1.60)b
0–24 1.21 (1.12, 1.31)c 1.30 (1.20, 1.41)c 0.86 (0.80, 0.93)c 1.11 (1.02, 1.21)a
Non diabetic population
0–6 0.96 (0.85, 1.09) 1.11 (0.98, 1.26) 0.53 (0.48, 0.58)c 0.79 (0.71, 0.87)c
6–12 1.12 (0.97, 1.29) 1.28 (1.10, 1.48)b 0.73 (0.65, 0.81)c 1.01 (0.90, 1.13)
12–18 1.18 (0.99, 1.41)a 1.35 (1.13, 1.61)c 0.93 (0.83, 1.05) 1.20 (1.06, 1.35)b
18–24 1.36 (1.10, 1.68)b 1.47 (1.18, 1.83)c 1.07 (0.93, 1.22) 1.36 (1.18, 1.57)c
0–24 1.07 (0.99, 1.16) 1.24 (1.14, 1.35)c 0.69 (0.65, 0.74)c 0.97 (0.91, 1.04)
a P  0.05; b P  0.01; c P  0.001 compared to a relative risk of 1.00
analyses in which we adjusted only for objective mea-
sures of disease at ESRD onset, namely, serum albumin
(an index of cumulative comorbidity), hematocrit, resid-
ual renal function, and BMI. Second, as we recently have
shown an effect modification between dialysis modality
and CAD with mortality, it is possible that a high correla-
tion of CAD with CHF could give rise to similar results
and therefore bias our analyses [10]. For this reason we
repeated our analyses in another series of statistic models
excluding patients with a history of CAD from the origi-
nal cohort. Finally, we considered the possibility of selec-
tion bias due to differences in the rates of renal trans-
plantation between peritoneal dialysis and hemodialysis
groups, differences that may result in “healthier” perito-
neal dialysis patients receiving a renal transplant while
leaving a relatively “sicker” fraction on peritoneal dial-
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Table 5. Relative risk of death for peritoneal disease (PD) versus hemodialysis (HD) among incident end-stage renal disease (ESRD)
patients with and without preexisting congestive heart failure (CHF): As-treated analysisa
CHF relative risk No CHF relative risk
Modality Unadjusted Adjusted Unadjusted Adjusted
Diabetic population
HDo (reference) 1 1.00 1.00 1.00 1.00
PDoa 1.20f 1.29f 0.78f 1.02
PD  HDnewb 1.38f 1.50f 1.35f 1.72f
HD  PDnewc 1.58f 1.72f 1.22d 1.39f
Nondiabetic population
HDo (reference)a 1.00 1.00 1.00 1.00
PDoa 1.05 1.21d 0.62f 0.90e
PD  HDnewb 1.32e 1.54f 1.14d 1.46f
HD  PDnewc 1.34f 1.45f 1.03 1.28f
a The as-treated analyses compared the mortality risks of patients who switched from one modality to another during the follow-up with those remaining on PD
(PDo) or HD (HDo) since ESRD start
b (HDnew), patients who switched from PD to HD
c (PDnew), patients who switched from HD to PD. Model adjusted for all covariates listed in Table 2.
d P  0.05; eP  0.01; fP  0.001 compared to a relative risk of 1.00
ysis. In each additional analysis, the association of perito-
neal dialysis with higher mortality risk among patients
with CHF persisted (data not shown).
DISCUSSION
Despite the widely held opinion that peritoneal dial-
ysis might be the better choice for new ESRD patients
with CHF given its positive effect on hemodynamic sta-
bility and volume regulation, this study suggests the con-
trary. Compared with hemodialysis, the selection of peri-
toneal dialysis was associated with significantly higher
mortality risks among new ESRD patients with a history
of CHF. The results were consistent in both diabetic and
nondiabetic subgroups, remained significant even after a
comprehensive adjustment for differences in measurable
baseline comorbidity and differences in transplantation
rates, and were confirmed in both “intent to treat” and
“as-treated” analyses. Moreover, this study demonstrates
that switches in modality therapy occurring after dialysis
initiation, independent of the direction of switch, are
associated with a worsened survival. These findings sug-
gest that the utilization of peritoneal dialysis among
ESRD patients with documented CHF may adversely
affect patient survival.
The increased mortality risk among CHF patients
treated with peritoneal dialysis was not constant over
time but increased with follow-up. Among diabetics with
CHF, the risk increased from 14% during the first 6
months to almost 40% at the end of the final 6 months of
the 2-year observation period. Similarly, for nondiabetics
with CHF, the relative risk of death increased from 11%
in the first 6 months to 47% in the final 6 months. These
findings suggest that the deleterious effect of peritoneal
dialysis on survival of ESRD patients with CHF is a
time-dependent phenomenon and suggest that the mech-
anism(s) through which this increased mortality occurs
may also be a function of time. The negative impact of
peritoneal dialysis on survival was also observed in the
diabetic group without CHF, at least in the “intent-to-
treat” analysis. However, the finding of similar survival
in the “as-treated” model suggests that the negative im-
pact of peritoneal dialysis in the “intent-to treat” may
be due to crossovers from hemodialysis who are doing
poorly and argue against a selective peritoneal dialysis
disadvantage. Moreover, the finding of a survival advan-
tage among nondiabetic patients without CHF in favor
of peritoneal dialysis (albeit modest) suggests that peri-
toneal dialysis is at least comparable to hemodialysis for
a large segment of the incident ESRD population.
Previous comparisons of peritoneal dialysis- and he-
modialysis-treated patients have not compared survival
outcomes in high-risk subgroups, especially those with
preexisting cardiovascular disease. Given the epidemic
of cardiovascular disease among newly diagnosed ESRD
patients, defining the optimal modality strategy in these
groups might reduce future morbidity and mortality
[19, 20]. The current study demonstrates a very signifi-
cant effect modification between dialysis modality, CHF,
and mortality in the nonrandomized observational set-
ting. This study does not, however, provide evidence for
the mechanism of increased mortality among peritoneal
dialysis–treated patients. There are, however, several
possibilities. First, the apparent short-term benefit of
peritoneal dialysis in maintaining volume control in CHF
patients through ultrafiltration may be offset by the long-
term negative impact of peritoneal dialysis on cardiac
performance. Prospective comparisons of peritoneal di-
alysis and hemodialysis patients have shown significantly
more left ventricular hypertrophy and poorer left ven-
tricular function among peritoneal dialysis–treated pa-
tients [5, 6, 21]. These deleterious consequences may in
part be due to alterations in peritoneal transport patterns
occurring over time in peritoneal dialysis–treated pa-
tients resulting in inadequate regulation of fluid balance
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[22]. Second, the loss of residual renal function and urine
volume over time among peritoneal dialysis–treated pa-
tients may further compromise overall volume regulation
and explain in part the deleterious effect of peritoneal
dialysis on survival [23, 24]. Indeed the time-dependent
increase in death risk with peritoneal dialysis as shown
in our study might correlate with the known rates of
decline in residual renal function and membrane trans-
port characteristics that are seen in peritoneal dialysis–
treated patients [25, 26]. Finally, it is also possible that
several other factors such as accelerated atherosclerosis,
increased infection rates, or specific differences in as-
pects of delivered clinical care between peritoneal dial-
ysis and hemodialysis might be responsible for the ob-
served mortality differences. Whatever the mechanism,
our results shown that despite the putative benefits of
peritoneal dialysis, the choice of hemodialysis confers a
significant survival advantage.
The optimal study design for comparing peritoneal
dialysis and hemodialysis treatment modalities would be
a randomized controlled clinical trial. This choice of exper-
imental design would ensure that any differences in out-
comes seen on follow-up would be solely due to one
treatment or the other. In the ideal setting, this experi-
mental design would virtually remove “treatment by in-
dication” bias or “selection bias” described above insur-
ing that the patients assigned to the respective treatment
modalities are approximately equivalent with respect to
all extraneous factors, regardless as to whether these
factors are known to the researcher [27, 28]. However,
given the logistic, feasibility, methodologic, and financial
concerns in designing and executing such a study, the
nonrandomized observational approach provides a rea-
sonably robust alternative scientific strategy. However,
such a study has inherent limitations. First, it cannot
replace the randomized controlled clinical trial and
therefore comparisons based on observational data may
be subject to several biases and lead to conflicting results
[1, 29–33]. These include selection bias between hemodi-
alysis and peritoneal dialysis, survival bias from analyses
of “prevalent” over “incident” cohorts, and statistic bias
that fail to account for time-dependent effects of treat-
ment modality on mortality [34, 35]. In an attempt to
overcome some of these limitations and permit unbiased
comparisons, we based our analyses on a nationally rep-
resentative cohort of newly diagnosed patients. We ad-
justed for several baseline differences present between
comparison groups. Indeed, our analyses show that pa-
tients assigned to peritoneal dialysis had on average
lower comorbidity levels, better laboratory values, and
greater residual renal function at ESRD onset than those
assigned to hemodialysis, favoring greater survival in
the peritoneal dialysis group. Finally, we have based our
observations on both “intent-to treat” as well as “as-
treated” analyses, thereby reducing bias resulting from
switches in treatment modalities during follow-up.
An additional concern in our study was the possible
underreporting of comorbid conditions from the CMS
Evidence Form, especially CHF, as this was our principal
stratifying variable [36]. In addition, differential reporting
of medical conditions in hemodialysis and peritoneal di-
alysis–treated patients may lead to insufficient adjust-
ment in multivariate analysis and bias modality compari-
sons. In response to these concerns, we demonstrated
that the prevalence of CHF in this study was 33%, similar
to reported estimates from several other nationally rep-
resentative studies [19, 37]. Moreover, sensitivity analy-
ses, adjusting only for objective measures of comorbidity
(BMI, hematocrit, serum albumin, and estimated GFR),
yielded estimates that were consistent with the overall
results. Finally, our study lacked prospective data on
residual renal function, delivered dose of dialysis, anemia
management, nutritional indices, and other clinical indi-
cators that may have varied with treatment modality and
time and influenced survival outcome.
To our knowledge this is the first comparative analysis
of hemodialysis and peritoneal dialysis survival among
new ESRD patients with CHF and has important impli-
cations. First, it demonstrates significantly poorer overall
survival in patients with CHF treated with peritoneal
dialysis as compared to hemodialysis, an observation that
was present in both diabetic and nondiabetic patients.
Second, it shows that negative impact of peritoneal dial-
ysis on survival is time-dependent, occurring as early
as 6 months after ESRD start and increasing as time
progresses. Although selection bias may explain the det-
rimental impact of peritoneal dialysis on survival, the
persistence of this finding after comprehensive adjust-
ment for potential confounding factors suggests that this
reduced survival may represent a true adverse peritoneal
dialysis–treatment effect. Nonetheless, this observation
may be due to differences in dialysis dose, rates of decline
in residual renal function, and cardiac risk factor profiles
between peritoneal dialysis and hemodialysis patients.
Finally, this study shows that for patients who do not
have CHF at ESRD onset, the choice of peritoneal dial-
ysis has similar survival outcomes compared with hemo-
dialysis. Taken together, these findings suggest that peri-
toneal dialysis, as is currently practiced, may not be a
suitable choice for new ESRD patients with CHF and
that hemodialysis may be preferred therapy. Given the
epidemic of cardiovascular disease and alarmingly high
prevalence of CHF in new ESRD patients, there is an
urgent need for detailed prospective studies comparing
peritoneal dialysis to hemodialysis in this population.
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